clearly been established as a mainstay therapy for patients with congestive heart failure (CHF), New York Heart Association functional class II to IV heart failure symptoms, and dyssynchrony.
C ardiac resynchronization therapy (CRT) has
clearly been established as a mainstay therapy for patients with congestive heart failure (CHF), New York Heart Association functional class II to IV heart failure symptoms, and dyssynchrony.
However, despite refinement in implantation tech- In the first analysis group, 4,631 subjects were included; they had baseline left ventricular ejection fractions (LVEFs) of 21% to 32%, a QRS duration of Both authors have reported that they have no relationships relevant to the contents of this paper to disclose. In addition, if we can reduce the nonresponder rate through improved patient selection, new pacing technology (e.g., multipoint pacing), or new optimization algorithms (e.g., adaptive CRT), will we then be able to also further reduce the incidence of VAs? More studies will clearly be needed to answer these questions. In the meantime, however, we should focus on 
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